Goldman Sachs is set to report second-quarter earnings — here’s what the Street expects

Goldman Sachs is set to report second-quarter earnings — here’s what the Street expects


Goldman Sachs CEO David Solomon speaks during the Goldman Sachs Investor Day at Goldman Sachs Headquarters in New York City, U.S., February 28, 2023. 

Brendan Mcdermid | Reuters

Goldman Sachs is scheduled to report second-quarter earnings before the opening bell Wednesday.

Here’s what Wall Street expects:

  • Earnings: $9.53 per share, according to LSEG
  • Revenue: $13.47 billion, according to LSEG
  • Trading Revenue: Fixed income of $3.28 billion, equities of $3.65 billion, per StreetAccount
  • Investing Banking fees: $1.9 billion, per StreetAccount

Goldman Sachs is set up to be a beneficiary of several trends in the second quarter.

Trading desks across Wall Street have benefited as President Donald Trump’s tariff policies have roiled markets for bonds, currencies, commodities and stocks.

Investment banking activity including mergers and debt issuance has exceeded expectations at rivals including JPMorgan Chase thanks to a sharp rebound in asset values from April lows.

That recovery in stock prices also bodes well for the firm’s asset and wealth management division.

Goldman Sachs gets the majority of its revenue from Wall Street activities including trading and investment banking. That can lead to outsized returns during boom times and underperformance when markets don’t cooperate.

Shares of the bank have climbed 23% this year.

On Tuesday, JPMorgan, Citigroup and Wells Fargo each posted results that topped analysts’ expectations for earnings and revenue.

This story is developing. Please check back for updates.



Source

Moderna says FDA refuses to review its application for experimental flu shot
Business

Moderna says FDA refuses to review its application for experimental flu shot

A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images The Food and Drug Administration has refused to start a review of Moderna‘s application for its experimental flu shot, the company announced Tuesday, in another sign of the […]

Read More
Estee Lauder sues Walmart alleging ‘despicable’ sale of counterfeit beauty products
Business

Estee Lauder sues Walmart alleging ‘despicable’ sale of counterfeit beauty products

Walmart Inc. signage during the company’s listing at the Nasdaq MarketSite in New York, US, on Tuesday, Dec. 9, 2025. Michael Nagle | Bloomberg | Getty Images Estee Lauder sued Walmart in California federal court over allegations the big-box retailer sold counterfeit beauty products on its website and didn’t do enough to ensure only authorized […]

Read More
How this French building behemoth wants to solve the U.S. housing dilemma
Business

How this French building behemoth wants to solve the U.S. housing dilemma

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox. French […]

Read More